Leukemic transformation in patients with myeloproliferative neoplasms: A population-based retrospective study

Rajesh Shrestha, Smith Giri, James Olen Armitage, Vijaya R Bhatt

Research output: Contribution to journalArticle

Abstract

Aim: This study determined the epidemiology of developing leukemic transformation in patients with myeloproliferative neoplasms (MPN). Methods: We utilized the Surveillance, Epidemiology and End Results 13 database to identify 83 cases of leukemic transformation in MPN (n = 9335). Results: The 5-year cumulative incidence of leukemic transformation was higher in male versus female (2.17 vs 1.09%; p < 0.001), and in myelofibrosis (2.19%; 95% CI: 1.36-3.34%), compared with essential thrombocythemia (0.37%; 95% CI: 0.19-0.65%) and polycythemia vera (0.72%; 95% CI: 0.46-1.07%; p < 0.001). Patients had a median survival of 2 months after leukemic transformation, worse in older patients and without any impact of prior MPN subtypes. Conclusion: Myelofibrosis has a higher risk of leukemic transformation. Overall survival is dismal regardless of MPN subtypes.

Original languageEnglish (US)
Pages (from-to)1239-1246
Number of pages8
JournalFuture Oncology
Volume13
Issue number14
DOIs
StatePublished - Jun 2017

Fingerprint

Retrospective Studies
Primary Myelofibrosis
Population
Neoplasms
Epidemiology
Essential Thrombocythemia
Polycythemia Vera
Survival
Databases
Incidence

Keywords

  • acute myeloid leukemia
  • hematologic/leukemia
  • myeloproliferative neoplasm
  • prognosis
  • risk factors
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Leukemic transformation in patients with myeloproliferative neoplasms : A population-based retrospective study. / Shrestha, Rajesh; Giri, Smith; Armitage, James Olen; Bhatt, Vijaya R.

In: Future Oncology, Vol. 13, No. 14, 06.2017, p. 1239-1246.

Research output: Contribution to journalArticle

@article{56ef5e65706847afb28e35869a317cde,
title = "Leukemic transformation in patients with myeloproliferative neoplasms: A population-based retrospective study",
abstract = "Aim: This study determined the epidemiology of developing leukemic transformation in patients with myeloproliferative neoplasms (MPN). Methods: We utilized the Surveillance, Epidemiology and End Results 13 database to identify 83 cases of leukemic transformation in MPN (n = 9335). Results: The 5-year cumulative incidence of leukemic transformation was higher in male versus female (2.17 vs 1.09{\%}; p < 0.001), and in myelofibrosis (2.19{\%}; 95{\%} CI: 1.36-3.34{\%}), compared with essential thrombocythemia (0.37{\%}; 95{\%} CI: 0.19-0.65{\%}) and polycythemia vera (0.72{\%}; 95{\%} CI: 0.46-1.07{\%}; p < 0.001). Patients had a median survival of 2 months after leukemic transformation, worse in older patients and without any impact of prior MPN subtypes. Conclusion: Myelofibrosis has a higher risk of leukemic transformation. Overall survival is dismal regardless of MPN subtypes.",
keywords = "acute myeloid leukemia, hematologic/leukemia, myeloproliferative neoplasm, prognosis, risk factors, survival",
author = "Rajesh Shrestha and Smith Giri and Armitage, {James Olen} and Bhatt, {Vijaya R}",
year = "2017",
month = "6",
doi = "10.2217/fon-2016-0510",
language = "English (US)",
volume = "13",
pages = "1239--1246",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Leukemic transformation in patients with myeloproliferative neoplasms

T2 - A population-based retrospective study

AU - Shrestha, Rajesh

AU - Giri, Smith

AU - Armitage, James Olen

AU - Bhatt, Vijaya R

PY - 2017/6

Y1 - 2017/6

N2 - Aim: This study determined the epidemiology of developing leukemic transformation in patients with myeloproliferative neoplasms (MPN). Methods: We utilized the Surveillance, Epidemiology and End Results 13 database to identify 83 cases of leukemic transformation in MPN (n = 9335). Results: The 5-year cumulative incidence of leukemic transformation was higher in male versus female (2.17 vs 1.09%; p < 0.001), and in myelofibrosis (2.19%; 95% CI: 1.36-3.34%), compared with essential thrombocythemia (0.37%; 95% CI: 0.19-0.65%) and polycythemia vera (0.72%; 95% CI: 0.46-1.07%; p < 0.001). Patients had a median survival of 2 months after leukemic transformation, worse in older patients and without any impact of prior MPN subtypes. Conclusion: Myelofibrosis has a higher risk of leukemic transformation. Overall survival is dismal regardless of MPN subtypes.

AB - Aim: This study determined the epidemiology of developing leukemic transformation in patients with myeloproliferative neoplasms (MPN). Methods: We utilized the Surveillance, Epidemiology and End Results 13 database to identify 83 cases of leukemic transformation in MPN (n = 9335). Results: The 5-year cumulative incidence of leukemic transformation was higher in male versus female (2.17 vs 1.09%; p < 0.001), and in myelofibrosis (2.19%; 95% CI: 1.36-3.34%), compared with essential thrombocythemia (0.37%; 95% CI: 0.19-0.65%) and polycythemia vera (0.72%; 95% CI: 0.46-1.07%; p < 0.001). Patients had a median survival of 2 months after leukemic transformation, worse in older patients and without any impact of prior MPN subtypes. Conclusion: Myelofibrosis has a higher risk of leukemic transformation. Overall survival is dismal regardless of MPN subtypes.

KW - acute myeloid leukemia

KW - hematologic/leukemia

KW - myeloproliferative neoplasm

KW - prognosis

KW - risk factors

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85021404722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021404722&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0510

DO - 10.2217/fon-2016-0510

M3 - Article

C2 - 28589759

AN - SCOPUS:85021404722

VL - 13

SP - 1239

EP - 1246

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -